tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), CASI Pharmaceuticals (CASI) and Inhibikase Therapeutics (IKT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Moderna (MRNAResearch Report), CASI Pharmaceuticals (CASIResearch Report) and Inhibikase Therapeutics (IKTResearch Report) with bullish sentiments.

Moderna (MRNA)

Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Moderna today and set a price target of $506.00. The company’s shares closed last Monday at $177.92.

According to TipRanks.com, Cann is a 3-star analyst with an average return of 3.3% and a 46.0% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Syros Pharmaceuticals, and Intellia Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moderna with a $217.89 average price target.

See Insiders’ Hot Stocks on TipRanks >>

CASI Pharmaceuticals (CASI)

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on CASI Pharmaceuticals today and set a price target of $12.00. The company’s shares closed last Monday at $3.66, close to its 52-week low of $2.24.

According to TipRanks.com, Ramakanth has 0 stars on 0-5 stars ranking scale with an average return of -3.7% and a 36.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Janux Therapeutics Inc, Harpoon Therapeutics, and Alaunos Therapeutics.

Currently, the analyst consensus on CASI Pharmaceuticals is a Strong Buy with an average price target of $31.00.

Inhibikase Therapeutics (IKT)

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Inhibikase Therapeutics, with a price target of $6.00. The company’s shares closed last Monday at $0.79, close to its 52-week low of $0.60.

According to TipRanks.com, Roy is a 4-star analyst with an average return of 5.7% and a 34.8% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Actinium Pharmaceuticals, and Adaptimmune Therapeutics.

Currently, the analyst consensus on Inhibikase Therapeutics is a Moderate Buy with an average price target of $6.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MRNA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More